With numerous economic factors in play, some firms seem to have focused portions of their testing portfolios on "low-hanging fruit" ï¿½ diagnostics for common ailments with predictable cycles of contagion, ones with a plethora of research funding, or ones for which research strongly supports the link between a nucleic acid detection and illness.